XOMA Royalty Corp

Senior XOMA Royalty Corp officers boost shares, showing confidence in the biotech royalty model that funds non‑dilutive drug development.

Explore how XOMA Royalty Corp’s $2.035‑per‑share buy of Mural Oncology could reshape biotech royalty dynamics and unlock high‑growth oncology revenue.

XOMA Royalty Corp has made two significant acquisitions, HilleVax and LAVA Therapeutics, in a bid to expand its portfolio and strengthen its position in the biotechnology sector.

XOMA Royalty Corp’s Q1 2025 earnings report highlights the company’s financial strength and strategic positioning in the biotech industry, despite market volatility and valuation challenges.